Streetbeat News

Revenues

GRVY

GRAVITY Co. (GRVY) reported a significant increase in Q3 earnings and sales compared to the same period last year. Earnings per share rose by 90.74% to $3.09 from $1.62, while sales surged by 82.75% to $130.69 million from $71.51 million.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:12 am

AUPH

Aurinia Pharmaceuticals Inc. announced that its partner Otsuka Pharmaceutical filed an NDA in Japan for LUPKYNIS (voclosporin) for lupus nephritis treatment. The FDA approved voclosporin in January 2021 for LN in the U.S. Under a collaboration agreement, Aurinia will receive $10 million upon Japan approval and royalties on sales.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:01 am

HSIC

Henry Schein (NASDAQ:HSIC) reported Q3 adjusted EPS of $1.32, which was in line with analyst estimates, and a 2.33% increase from the previous year. However, sales of $3.16B fell short of the expected $3.21B, a miss by 1.50%, though they were up 3.10% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:01 am

BP

EIX

SHEL

BP PLC, Shell PLC, and Edison International have sought assistance from the U.S.-EU Task Force on Energy Security in a dispute with Venture Global LNG regarding undelivered LNG cargoes. Shell and BP have expressed concerns over Venture Global's reliability and the potential loss of trust in U.S. LNG suppliers. Venture Global has been accused of prioritizing a new plant over completing repairs on the existing one. U.S. and EU officials view the matter as a contractual dispute. Shell and BP recently reported Q3 financial results, with Shell's earnings per ADS above consensus but revenue below, and BP's sales and underlying RC profit per ADS both missing consensus estimates.

Portfolio Pulse from Lekha Gupta

November 13, 2023 | 10:52 am

FXI

China's new loans for October amounted to 738.4 billion yuan, surpassing the estimated 665.0 billion yuan and showing a decrease from the prior figure of 2,310.0 billion yuan.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:49 am

BA

China is reportedly considering lifting its commercial ban on Boeing Co.'s 737 Max, potentially announcing a deal during the APEC Summit. Relations between China and the U.S. are improving, which may lead to a breakthrough in sales for Boeing. The 737 Max, a significant revenue source for Boeing, has been grounded in China since 2019 following two fatal crashes. A deal would be pivotal for Boeing, especially as the travel industry recovers and aircraft demand increases.

Portfolio Pulse from Anan Ashraf

November 13, 2023 | 3:43 am

MA

V

VCR

XRT

Finance experts are advising consumers to save during the holiday season due to high inflation and interest rates. Savings accounts, CDs, and bonds are offering returns up to 5%, making spending less attractive. High credit card rates, which can approach 30%, also discourage spending. The Wall Street Journal suggests reviewing past expenses and setting spending limits with family to avoid overspending. Visa Inc. (V), Mastercard Inc. (MA), SPDR S&P Retail ETF (XRT), and Vanguard Consumer Discretionary ETF (VCR) are stocks and ETFs to watch as they are impacted by consumer spending and credit usage.

Portfolio Pulse from Bibhu Pattnaik

November 12, 2023 | 10:04 pm

BABA

Alibaba Group's subsidiaries, Taobao and Tmall, reported positive year-over-year growth in Gross Merchandise Volume (GMV), order numbers, and participating merchants for their 15th annual 11.11 Shopping Festival.

Portfolio Pulse from Charles Gross

November 12, 2023 | 3:50 pm

LLY

NVO

Novo Nordisk's (NYSE:NVO) weight loss drug Wegovy has been shown in a clinical trial to significantly reduce the risk of serious heart complications by 20% in obese individuals without diabetes. The Select study's results could lead to broader insurance coverage and increased usage of Wegovy, potentially maintaining Novo Nordisk's lead over Eli Lilly (NYSE:LLY), whose weight-loss drug Zepbound was recently approved in the U.S. Despite some participants discontinuing Wegovy due to gastrointestinal issues, the drug also showed a 73% reduction in progression to diabetes.

Portfolio Pulse from Benzinga Neuro

November 11, 2023 | 9:34 pm

CLF

GS

MT

RIO

VALE

Goldman Sachs (NYSE:GS) forecasts an iron ore supply deficit by year-end due to reduced production and low inventories, particularly highlighting issues with Vale's (NYSE:VALE) output. China's increased fiscal spending could boost demand, but the property crisis remains a concern. Goldman raised its iron ore price forecast for 2023 and 2024. The deficit may impact companies like Rio Tinto (NYSE:RIO), Cleveland-Cliffs (NYSE:CLF), and Arcelor Mittal (NYSE:MT).

Portfolio Pulse from Nabaparna Bhattacharya

November 11, 2023 | 7:50 pm